HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Huntington's Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 11 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University College, London
- Last updated on ClinicalTrials.gov
- April 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Cenexel · Englewood, CO
District of Columbia · 1
- Georgetown University · Washington D.C., DC
Maryland · 1
- John Hopkins University · Baltimore, MD
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Texas · 1
- University of Texas Health Science Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.